✦ LIBER ✦

A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)

✍ Scribed by Sara A. Hurvitz; Heather J. Allen; Rebecca L. Moroose; David Chan; Christopher Hagenstad; Steven H. Applebaum; Giribala Patel; Eddie H. Hu; Nancy Ryba; Lii-Shin Lin; HeJing Wang; John Glaspy; Dennis J. Slamon; Fairooz Kabbinavar

Book ID: 115075873
Publisher: CIG Media Group, LP.
Year: 2010
Tongue: English
Weight: 598 KB
Volume: 10
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2010.n.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Final results of a phase II study of bev

Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01)

✍ S. Hurvitz; H.J. Allen; R.L. Moroose; D. Chan; C. Hagenstad; S.H. Applebaum; G. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Biomarker results from the AVADO phase 3

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

✍ Miles, D W; de Haas, S L; Dirix, L Y; Romieu, G; Chan, A; Pivot, X; Tomczak, P; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 366 KB

A multicenter phase I–II study of doceta

A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer

✍ Tryfonidis, K.; Boukovinas, I.; Xenidis, N.; Christophyllakis, C.; Papakotoulas, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 348 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB